Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma

Experimental Oncology

Volumn 34, Issue 1, 2012, Pages 17-24

  Petrushev, B ^a   Tomuleasa, C ^b,c   Soritau, O ^c   Aldea, M ^a   Pop, T ^a,d   Susman, S ^a   Kacso, G ^a,c   Berindan, I ^a,c   Irimie, A ^a,c   Cristea, V ^a,d  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ion Chiricuta Comprehensive Cancer Center   (Romania)

^d Octavian Fodor Regional Institute of Gastroenterology and Hepatology   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUORESCEIN DIACETATE; GLUTATHIONE; METFORMIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ALPHA2A INTERFERON;

ADD ON THERAPY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL CARCINOMA; OXIDATIVE STRESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; METFORMIN;

EID: 84862487671     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Papavramidou N, Fee E, Christopoulou-Aletra H. Jaundice in the Hippocratic corpus. J Gastrointest Surg 2007; 11: 1728-31.
2. Lykouras E, Poulakou-Rebelakou E, Ploumpidis DN. Searching the seat of the soul in Ancient Greek and Byzantine medical literature. Acta Cardiol 2010; 65: 619-26.
3. Reuben A. The way to a man's heart is through his liver. Hepatology 2003; 37: 1500-2. (Pubitemid 36667336)
4. Hammerschmidt DE. Prometheus. J Lab Clin Med 2000; 135: 498.
5. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
7. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52: iii1-8. (Pubitemid 36520856)
8. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010; 16: 1695-700.
9. Soritau O, Tomuleasa C, Aldea M, et al. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON 2011; 16: 282-9.
10. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-302.
11. von Delius S, Lersch C, Mayr M, et al. Capecitabine for treatment of advanced hepatocellular carcinom ma. Hepatogastroenterology 2007; 54: 2310-4.
12. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-8. (Pubitemid 41631953)
13. Tomuleasa C, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 2010; 19: 61-7.
14. Tomuleasa C, Soritau O, Fischer-Fodor E, et al. Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 2011; 4: 60-6.
15. Korde SD, Basak A, Chaudhary M, et al. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. Oncology 2011; 80: 382-9.
16. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63. (Pubitemid 351615415)
17. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
18. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-6.
19. Suh YJ, Kim MJ, Choi JY, et al. Differentiation of hepatic hyperintense lesions seen on gadoxetic acidenhanced hepatobiliary phase MRI. Am J Roentgenol 2011; 197: W44-52.
20. El-Serag HB. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 2011; 4: 5-10.
21. Llovet JM, Br C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
22. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
23. Varotti G, Ramacciato G, Ercolani G, et al. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 2005; 31: 760-7. (Pubitemid 41194654)
24. Zhou L, Rui JA, Wang SB, et al. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy. J Surg Res 2010; 159: 538-44.
25. Zhou L, Rui JA, Ye DX, et al. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg 2008; 32: 1748-56.
26. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9: 33.
27. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128: 783-94.
28. Burhans WC, Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 2009; 47: 1282-93.
29. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. Br J Surg 2010; 97: 628-42.
30. Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol 2011; 5: 223-31.
31. Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev 2011; 27: 419-24.
32. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis 2010; 9: 42.
33. Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011; 2011: 592-404.
34. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 2009; 17: 1696-701.
35. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-71.